OTLK Overview
Upcoming Projects (OTLK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (OTLK)
-
A Third Look: Digging into the Phase 3 NORSE TWO clinical trial of LYTENAVA (bevacizumab-vikg) in patients with wet age-related macular degeneration.
Tickers: OTLK, RHHBY
Executed On: Aug 15, 2023 at 06:15 PM EDT -
A Second Look: Digging into the Phase 3 NORSE TWO clinical trial of LYTENAVA (bevacizumab-vikg) in patients with wet age-related macular degeneration.
Tickers: OTLK, RHHBY
Executed On: Aug 08, 2023 at 11:00 AM EDT -
Digging into the Phase 3 NORSE TWO clinical trial of LYTENAVA (bevacizumab-vikg) in patients with wet age-related macular degeneration.
Tickers: OTLK, RHHBY
Executed On: Jul 12, 2023 at 12:00 PM EDT -
Discussing the commercial outlook of Coherus' Cimerli (ranibizumab biosimilar) and Outlook's Lytenava (ophthalmic formulation of bevacizumab) in Wet AMD
Tickers: CHRS, OTLK
Executed On: Mar 17, 2023 at 12:00 PM EDT
Upcoming & Overdue Catalysts (OTLK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (OTLK)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
